Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial: Sensitivity Analyses Further Support the Primary Results
Year: 2018
Type: article
Source: Journal of Cardiac Failure
Authors: Mathew S. Maurer, Jeffrey H. Schwartz, Balarama Gundapaneni, Perry Elliott, Giampaolo Merlini, Márcia Waddington Cruz, Arnt V. Kristen, Martha Grogan, Ronald Witteles, Thibaud Damy, Brian M. Drachman, Sanjiv J. Shah, Mazen Hanna, Daniel P. Judge, Stephen S. Gottlieb, John L. Berk, Daniel J. Lenihan, James E. Hoffman, Scott L. Hummel, Eric J. Velazquez, Terrell A. Patterson, Marla B. Sultan, Claudio Rapezzi
Institutions: Columbia University, Pfizer (United States), Syneos Health (United States), University College London, University of Pavia, Universidade Federal do Rio de Janeiro, Heidelberg University, Mayo Clinic, Stanford Medicine, Stanford University, Inserm, Centre Hospitalier Universitaire Henri-Mondor, Penn Presbyterian Medical Center, University of Pennsylvania Health System, Northwestern University, Cleveland Clinic, Medical University of South Carolina, University of Maryland, Baltimore, Boston University, Washington University in St. Louis, University of Miami, University of Michigan, Yale New Haven Health System, University of Bologna
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Funder: Pfizer
OpenAlex ID: W2903372043